Periodic Safety Update Report (PSUR)

Periodic Safety Update Report (PSUR)

  1. Feb 28, 2025

What Does the ‘Periodic Safety Update Report (PSUR)’ Mean?

A Periodic Safety Update Report (PSUR) is a pharmacovigilance document submitted by pharmaceutical companies to regulatory authorities at defined time points after a drug’s authorization. It provides a comprehensive analysis of the risk-benefit balance of a medicinal product, taking into account new or emerging safety information in the context of cumulative information on benefits and risks.

PSURs are crucial for ongoing safety monitoring and evaluation of marketed drugs. They include summaries of safety data from clinical trials, post-marketing surveillance, and scientific literature, as well as an integrated benefit-risk evaluation to ensure the continued safe and effective use of the product.

Why Is the ‘Periodic Safety Update Report (PSUR)’ Important in Clinical Research?

PSURs are essential in clinical research as they provide a systematic approach to post-marketing safety surveillance of medicinal products. They allow regulatory authorities and pharmaceutical companies to continuously monitor and evaluate the safety profile of drugs throughout their lifecycle, ensuring that any new risks or changes in known risks are promptly identified and addressed.

The importance of PSURs extends beyond individual products, contributing to the overall safety of public health. By aggregating and analyzing safety data from various sources, PSURs help in detecting rare adverse events, identifying potential safety signals, and facilitating timely regulatory actions or updates to product information, thereby enhancing patient safety and improving the benefit-risk profile of medicines.

Good Practices and Procedures

  1. Establish a cross-functional PSUR team involving pharmacovigilance, clinical, regulatory, and medical writing experts to ensure comprehensive data collection and analysis.
  2. Implement a robust literature screening process to capture relevant published safety information, including setting up automated alerts for newly published studies.
  3. Develop standardized templates and checklists for each PSUR section to maintain consistency and ensure all required elements are included across different products and reporting periods.
  4. Conduct regular internal audits of the PSUR preparation process to identify areas for improvement and ensure compliance with evolving regulatory requirements.
  5. Establish a system for tracking and incorporating feedback from regulatory authorities on previous PSURs to enhance the quality and relevance of future submissions.

Related Terms

Resources

Large Language Models in Nuclear Cardiology: From Experimental Tools to Clinical Infrastructure

3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…

From Half-Life to Clinical Impact: Mastering Time-Critical Supply Chains

How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…

How ACT EU Is Forcing a Global Approach to Trial Timelines

Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…